185 related articles for article (PubMed ID: 15722313)
1. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study.
Jonas JB; Akkoyun I; Kreissig I; Degenring RF
Br J Ophthalmol; 2005 Mar; 89(3):321-6. PubMed ID: 15722313
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.
Jonas JB; Kreissig I; Degenring RF
Br J Ophthalmol; 2004 Dec; 88(12):1557-62. PubMed ID: 15548812
[TBL] [Abstract][Full Text] [Related]
3. Cataract surgery combined with intravitreal injection of triamcinolone acetonide.
Jonas JB; Kreissig I; Budde WM; Degenring RF
Eur J Ophthalmol; 2005; 15(3):329-35. PubMed ID: 15945000
[TBL] [Abstract][Full Text] [Related]
4. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema.
Spandau UH; Derse M; Schmitz-Valckenberg P; Papoulis C; Jonas JB
Br J Ophthalmol; 2005 Aug; 89(8):999-1003. PubMed ID: 16024853
[TBL] [Abstract][Full Text] [Related]
5. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide.
Jonas JB; Spandau UH; Harder B; Vossmerbaeumer U; Kamppeter BA
Am J Ophthalmol; 2005 Jun; 139(6):1073-9. PubMed ID: 15953439
[TBL] [Abstract][Full Text] [Related]
6. [Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macular oedema].
Jonas JB; Degenring R
Klin Monbl Augenheilkd; 2002 Jun; 219(6):429-32. PubMed ID: 12136438
[TBL] [Abstract][Full Text] [Related]
7. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study.
Jonas JB; Degenring RF; Kreissig I; Friedemann T; Akkoyun I
Eye (Lond); 2005 Feb; 19(2):163-70. PubMed ID: 15218517
[TBL] [Abstract][Full Text] [Related]
8. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.
Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B; Sauder G
Ophthalmology; 2006 May; 113(5):800-4. PubMed ID: 16530840
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
Cheng KC; Wu WC; Chen KJ
Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular oedema. Combined IVTA and laser treatment for PDR with CSMO.
Kaderli B; Avci R; Gelisken O; Yucel AA
Int Ophthalmol; 2005 Dec; 26(6):207-14. PubMed ID: 17356929
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
Sheth S; Rush R; Natarajan S; Gillies M
Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
[TBL] [Abstract][Full Text] [Related]
12. Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide.
Jonas JB; Harder B; Kamppeter BA
Am J Ophthalmol; 2004 Dec; 138(6):970-7. PubMed ID: 15629288
[TBL] [Abstract][Full Text] [Related]
13. Intraocular pressure after intravitreal injection of triamcinolone acetonide.
Jonas JB; Kreissig I; Degenring R
Br J Ophthalmol; 2003 Jan; 87(1):24-7. PubMed ID: 12488256
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration.
Jonas JB; Ihloff AK; Harder B; Kreissig I; Schlichtenbrede F; Libondi T; Spandau UH; Vossmerbaeumer U
Ophthalmic Res; 2009; 41(1):21-7. PubMed ID: 18849638
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study.
Brasil OF; Smith SD; Galor A; Lowder CY; Sears JE; Kaiser PK
Br J Ophthalmol; 2007 Jun; 91(6):761-5. PubMed ID: 17108013
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.
Jonas JB; Akkoyun I; Budde WM; Kreissig I; Degenring RF
Arch Ophthalmol; 2004 Feb; 122(2):218-22. PubMed ID: 14769599
[TBL] [Abstract][Full Text] [Related]
17. Visual acuity and contrast sensitivity outcomes in Indian eyes undergoing photodynamic therapy with intravitreal injection of triamcinolone acetonide in age-related macular degeneration.
Kumar A; Sinha S; Kumar V
Indian J Ophthalmol; 2007; 55(3):207-11. PubMed ID: 17456939
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal cortisone injection for refractory diffuse diabetic macular edema.
Er H; Yilmaz H
Ophthalmologica; 2005; 219(6):394-400. PubMed ID: 16286802
[TBL] [Abstract][Full Text] [Related]
19. Outcome of intravitreal triamcinolone acetonide in postoperative cystoid macular oedema.
Konstantopoulos A; Williams CP; Luff AJ
Eye (Lond); 2008 Feb; 22(2):219-22. PubMed ID: 17016463
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion.
Patel PJ; Zaheer I; Karia N
Eye (Lond); 2008 Jan; 22(1):60-4. PubMed ID: 16902493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
